Xhance
-
After Fielding Multiple Offers, Yardley-Based Optinose Secures Potential $330M Deal With Paratek
Yardley-based Optinose, which put itself up for auction three years ago attracting multiple suitors, has secured a potential $330 million deal with Paratek, writes John…
-
Paratek Pharmaceuticals Acquires Yardley-Based Optinose in $330M Deal
Paratek Pharmaceuticals of Boston has entered into a definitive agreement to buy Yardley-based Optinose in a deal worth up to $330 million, writes John George…
-
Yardley-Based Optinose’s Xhance Nasal Spray Wins FDA Nod for Chronic Rhinosinusitis
Yardley-based Optinose got the green light from the Food and Drug Administration for their flagship nasal spray Xhance, writes John George for the Philadelphia Business…
-
Optinose Awaits FDA Verdict on Expansion for Chronic Rhinosinusitis Treatment
Yardley-based Optinose, known for its drug-device product Xhance, is at a pivotal moment as it awaits a decision from the Food and Drug Administration, writes…
-
Optinose, Yardley, Looks to Raise $40M — Nothing to Sneeze at — to Expand Nasal Drug Delivery Device Line
Late last week, Optinose of Yardley closed its effort to raise $40 million through the sale of company stock. The capital infusion will expand its…
Founding Partners
Advertisement
Affiliate Partners
